Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8+ T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients
NAGIOS: RODERIC FUNCIONANDO

Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8+ T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients

DSpace Repository

Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8+ T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients

Show full item record

View       (123.1Kb)

    
Giménez Quiles, Estela Berenice; Solano Vercet, Carlos; Azanza, José Ramón; Amat Martínez, Paula; Navarro Ortega, David
This document is a artículoDate2014

Este documento está disponible también en : http://hdl.handle.net/10550/44423
It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8+ T cells) appeared to perform better for this purpose.

    Antimicrobial Agents and Chemotherapy Vol. 58 Issue 9: pp. 5602-5605

This item appears in the following Collection(s)

Show full item record

Search DSpace

Advanced Search

Browse

Statistics